16 Nov 2026 Recon: FDA rejects ivonescimab for lung cancer indication; J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
12 Nov 2026 Recon: FDA shelves commissioner's voucher program; Eli Lilly gets first GLP-1 weight-loss pill approved in China Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
10 Nov 2026 Recon: Bayer wins FDA approval for stroke prevention drug; Third Rock enters $2B partnership with AI-focused Chinese biotech Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
09 Nov 2026 Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer cases Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
05 Nov 2026 Recon: Sino, Boehringer ink cancer drug deal worth $7B; CVS to split pharmacy business from insurance Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
03 Nov 2026 Recon: Merck KGaA to exit CDMO business; Karyopharm to sell itself in bankruptcy Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
02 Nov 2026 Recon: FDA approves generic lenacapavir intended for lower income countries; EMA to review Lundbeck's Deanxit for reported serious side effects Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
29 Oct 2026 Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetes Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
27 Oct 2026 Recon: FDA approves treatments for prostate cancer, Crohn’s disease; US judge refuses to halt Lilly weight-loss drug ads Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
26 Oct 2026 Recon: FDA approves Edwards’ tricuspid valve repair device; Bayer wins Chinese approval for blood thinner asundexian Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon